First human tests begin for Next-Generation meningitis shot
NCT ID NCT07395739
Summary
This early-stage study aims to test the safety and immune response of a new vaccine (DX-104) designed to protect against meningitis B. It will involve 30 healthy adults aged 18-50, who will receive three shots over six months. The new vaccine's safety and ability to trigger protective antibodies will be compared against an existing approved vaccine.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEISSERIA MENINGITIDIS SEROGROUP B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Linear Early Phase Limited
Perth, Western Australia, 6009, Australia
Conditions
Explore the condition pages connected to this study.